Find clinical trials for Glioblastoma (GBM) in Washington, DC
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Glioblastoma (GBM) trials near Washington, DC, USA:
FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM...
Phase 1
Baltimore, Maryland, United States and 8 other locations
The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma...
Phase 2
Washington D.C., District of Columbia, United States and 23 other locations
the feasibility of adding MRSI to the evaluation of newly-diagnosed GBM patients treated with standard RT/TMZ and determine whether magnetic...
Phase 2
Baltimore, Maryland, United States and 1 other location
Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the stud...
Phase 3
Washington D.C., District of Columbia, United States and 100 other locations
are also impermeable to the passage of therapeutic molecules from the blood to the brain. The development of effective treatments against glioblastoma...
Phase 3
Baltimore, Maryland, United States and 50 other locations
growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM...
Phase 1, Phase 2
Washington D.C., District of Columbia, United States and 28 other locations
This phase I trial studies the side effects of stereotactic radiosurgery with MBG453 and spartalizumab in treating patients with recurrent glioblastoma...
Phase 1
Baltimore, Maryland, United States and 1 other location
This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and ch...
Phase 2
Fairfax, Virginia, United States and 11 other locations
via ICV in participants with recurrent or progressive IDH-wildtype glioblastoma (WHO 2021 CNS Grade 4), who have previously received standar...
Phase 2
Baltimore, Maryland, United States and 3 other locations
Clinical trials
Research sites
Resources
Legal